BioSpace News Archive

BioMidwest

On Target Laboratories Secures $30 Million for Commercialization of CYTALUX® (pafolacianine) injection

On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative molecular imaging agents to target and illuminate cancer during surgery, today announced the completion of a $30 million Series C financing.

November 16, 2023
·
5 min read
Drug Development

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Dermata Therapeutics, Inc. announces agreement with the U.S. Food and Drug Administration (FDA) on the DMT310 Phase 3 clinical protocols for the treatment of acne.

November 16, 2023
·
6 min read
Business

SHINE Technologies and Nucleus RadioPharma Partner to Advance Radioligand Cancer Treatments

SHINE Technologies today announced a long-term supply agreement with Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals.

November 16, 2023
·
4 min read
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

NLS Pharmaceutics Ltd. today announced that it is conducting an ongoing process to explore strategic alternatives to maximize shareholder value.

November 16, 2023
·
5 min read
Genetown

Fractyl Health Expands Landmark Academic-Industry Collaboration to Study Mechanisms Underlying GLP-1-Based Pancreatic Gene Therapy for Type 2 Diabetes and Obesity

Fractyl Health announced the expansion of an academic-industry scientific partnership charged with advancing research on the role of the gut and pancreas in metabolic disease.

November 16, 2023
·
4 min read
Biotech Bay

Cellecta, Inc. Launches DriverMap™ Adaptive Immune Receptor (AIR) Mouse RNA TCR and BCR Kits for Sensitive Immune Repertoire Profiling

Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) Mouse RNA TCR and BCR kits.

November 16, 2023
·
3 min read
Deals

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. today announced that it has received a notification letter (the “ Compliance Notice ”) from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC informing Alzamend that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).

November 16, 2023
·
3 min read